论文部分内容阅读
拉米夫定(Lamivudine,简称3TC)是具有强大抑制病毒作用的新一代核苷类药物。我国药品监督管理局及美国FDA在1998年底批准该药用于治疗慢性乙型肝炎(CHB)。经国内外5年多临床研究,治疗乙型肝炎病毒(HBV)感染者5000多例,发表论文近200篇,结果证明:拉米夫定在细胞内磷酸化为三磷酸拉米夫定后发挥其抑制逆转录酶,阻断病毒DNA合成与复制作用。临床治疗CHB患者,可降低体内HBV病毒水平,降低ALT水平和胆红素水平,恢复肝功能;亦可明显改善肝组织学,包括已形成的肝纤维化、肝硬
Lamivudine (referred to as 3TC) is a new generation of nucleoside drugs with a strong inhibitory effect on the virus. China’s Drug Administration and the United States FDA approved the drug in the end of 1998 for the treatment of chronic hepatitis B (CHB). After more than five years of clinical research at home and abroad, more than 5,000 cases of hepatitis B virus (HBV) infection have been treated and nearly 200 papers have been published. The results show that lamivudine plays an important role in intracellular phosphorylation of lamivudine triphosphate It inhibits reverse transcriptase and blocks viral DNA synthesis and replication. Clinical treatment of CHB patients, can reduce the level of HBV in vivo, reduce the level of ALT and bilirubin, restore liver function; can also significantly improve liver histology, including the formation of liver fibrosis, liver cirrhosis